BYSI Stock Overview
A clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BeyondSpring Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.62 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$0.78 |
| Beta | 0.23 |
| 1 Month Change | -16.32% |
| 3 Month Change | -32.99% |
| 1 Year Change | 79.44% |
| 3 Year Change | -67.76% |
| 5 Year Change | -89.25% |
| Change since IPO | -90.39% |
Recent News & Updates
Recent updates
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
Jun 21
BeyondSpring, Beyond Salvage
Feb 03Circling Back On BeyondSpring
Nov 16Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns
Sep 18BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk
Sep 07BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space
Aug 01BeyondSpring EPS misses by $0.04
Jun 16BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia
Jun 07FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%
Jun 01BeyondSpring EPS misses by $0.17
Apr 30How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?
Dec 22
BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution
Dec 15BeyondSpring slides 9% on public offering pricing at $10.0/share
Nov 19BeyondSpring under pressure on shares offering
Nov 17BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial
Nov 16Shareholder Returns
| BYSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.7% | 0.7% | 0.6% |
| 1Y | 79.4% | -3.4% | 23.7% |
Return vs Industry: BYSI exceeded the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: BYSI exceeded the US Market which returned 23.7% over the past year.
Price Volatility
| BYSI volatility | |
|---|---|
| BYSI Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BYSI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BYSI's weekly volatility has decreased from 17% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 36 | Lan Huang | beyondspringpharma.com |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company’s lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type.
BeyondSpring Inc. Fundamentals Summary
| BYSI fundamental statistics | |
|---|---|
| Market cap | US$65.09m |
| Earnings (TTM) | -US$15.57m |
| Revenue (TTM) | US$1.88m |
34.7x
P/S Ratio-4.2x
P/E RatioIs BYSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BYSI income statement (TTM) | |
|---|---|
| Revenue | US$1.88m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.88m |
| Other Expenses | US$17.44m |
| Earnings | -US$15.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 100.00% |
| Net Profit Margin | -829.85% |
| Debt/Equity Ratio | 0% |
How did BYSI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 09:00 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BeyondSpring Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| Joshua Schimmer | Evercore ISI |